To further understand the role of gene single nucleotide polymorphism (SNP) in the occurrence of type 2 inflammation-related asthma in children by analyzing the gene single nucleotide polymorphism (SNP), lung function and type 2 inflammation indicators of children diagnosed with asthma in outpatient and inpatient. To provide a theoretical basis for the study of personalized treatment and prevention strategies for asthma.
Eligibility
Sex
ALL
Min age
3 Years
Max age
14 Years
Healthy volunteers
Accepted
Inclusion Criteria:
1. All children with asthma diagnosis accord with the GINA in 2023 edition;
2. Other diseases that could cause wheezing and cough were excluded, such as acute laryngitis, diphtheria, congenital airway abnormalities, and tracheal foreign bodies;
3. In front of the hospital 2 weeks without antibiotics, systemic hormone medication history;
4. There were no other complications, such as congenital heart disease, pneumonia, gastroesophageal reflux disease, muscle dysplasia, etc.
Exclusion Criteria:
1. Children who had taken immunosuppressants, antibiotics and other drugs for a long time before admission;
2. Children with primary immunodeficiency disease;
3. The children and their families failed to cooperate or refused the experimental observation.
Primary outcome measure(s)
type 2 inflammation indicators — Outpatient visits for the first time Fraction of exhaled nitric oxide(FeNO)、Blood eosinophil count、Percentage of sputum eosinophils and Serum total immunoglobulin E
pulmonary function indicators — Outpatient visits for the first time Forced expiratory volume in one second(FEV1)、Forced vital capacity(FVC)、Ratio of forced expiratory volume in one second to forced vital capacity(FEV1/FVC) and Peak expiratory flow(PEF)
single nucleotide polymorphism — Outpatient visits for the first time Differences in SNPs of genes detected in children's blood samples
Trial sites (1)
Facility
City
Region
Status
Guangzhou institute of respiratory disease
Guangzhou
Guangdong
Recruiting
More Guangzhou Institute of Respiratory Disease trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.